Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma:a single-institution experience

作     者：CONSTANTINE N.LOGOTHETIS NATHAN P.HORVAT TONY KURIAN CELESTE BELLO JULIO CHAVEZ LEIDY ISENALUMHE BIJAL SHAH LUBOMIR SOKOL HAYDER SAEED JAVIER PINILLA SAMEH GABALLA 

作者机构：Department of Internal MedicineUniversity of South FloridaTampaFL33602USA College of MedicineUniversity of South Florida MorsaniTampaFL33602USA H.Lee Moffitt Cancer Center and Research InstituteTampaFL33612USA 

出 版 物：《Oncology Research》 (肿瘤学研究（英文）)

年 卷 期：2024年第32卷第6期

页      面：1031-1036页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Extranodal marginal zone lymphoma Bendamustine Rituximab Front-line therapy 

摘      要：Extranodal marginal zone lymphoma(EMZL)encompasses 70%of cases of marginal zone *** bendamustine and rituximab(BR)were derived from trials involving other indolent non-Hodgkin’s *** one trial has evaluated frontline BR prospectively in *** retrospective study reports outcomes among EMZL patients receiving frontline ***-five patients were included with a median age of 69 years(40–81).Five(20.0%)patients had stage Ⅰ/Ⅱ disease,and 20(80.0%)had stage Ⅲ/Ⅳ *** median number of cycles was 6.0(3.0–6.0).Maintenance rituximab was administered to 10(41.7%)*** response rate(ORR)was 100.0%(60.0%complete response,40.0%partial response).Medians of overall survival and progression-free survival were not *** estimated 2-year progression-free survival was 85.2%and overall survival was 100.0%.Four(16.6%)patients had infections related to treatment;3(12.0%)transformed to diffuse large B-cell lymphoma;5(20.8%)had a relapse or progression of EMZL;and 3(12.0%)died unrelated to *** is an efficacious and well-tolerated front-line regimen for EMZL with response data consistent with existing literature.